• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Biosimilars Policy Roundup for September 2024—Podcast Edition

News
Podcast

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.

On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.

Show notes

1. FDA Approves Pavblu for Retinal Conditions

2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1

3. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys

4. The Future of Biosimilar Gene Therapies: Key Issues and Potential

5. IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share

6. The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings

7. France Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD

Recent Videos
Sophia Humphreys, PharmD
Ha Kung Wong, JD.
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Michael Kleinrock
Ian Henshaw
Related Content
© 2024 MJH Life Sciences

All rights reserved.